NCT06136572

Brief Summary

The goal of this study is to evaluate the proportion of assertiveness difficulties in Tourette syndrome. Participants will complete several e-questionnaires (on assertiveness, Tourette severity, quality of life, self-esteem and comorbidities like depression, anxiety...).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for not_applicable

Timeline
5mo left

Started May 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
May 2024Nov 2026

First Submitted

Initial submission to the registry

November 13, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
6 months until next milestone

Study Start

First participant enrolled

May 6, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 5, 2026

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 5, 2026

Expected
Last Updated

February 27, 2026

Status Verified

February 1, 2026

Enrollment Period

2 years

First QC Date

November 13, 2023

Last Update Submit

February 25, 2026

Conditions

Tourette Syndrome

Outcome Measures

Primary Outcomes (1)

  • Rathus assertiveness questionnaire

    The Rathus assertiveness questionnaire includes 30 items, each scores from -3 to +30. A total score inferior or equal to -9 reveals assertiveness difficulties.

    5 minutes at inclusion

Secondary Outcomes (6)

  • MOVES

    less than 5 minutes at inclusion

  • HADS

    3 minutes at inclusion

  • ASRS-5

    2 minutes at inclusion

  • Rosenberg Self-Esteem Scale

    2-3 minutes at inclusion

  • DERS

    5 minutes at inclusion

  • +1 more secondary outcomes

Study Arms (1)

Rathus Assertiveness scale

EXPERIMENTAL

All participants

Diagnostic Test: Rathus Assertiveness scale

Interventions

Rathus Assertiveness scaleDIAGNOSTIC_TEST

Questionnaire completion

Rathus Assertiveness scale

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Tourette syndrome
  • Participants aged 18 years or over

You may not qualify if:

  • Participants under legal protection
  • Inability to complete questionnaires alone

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Clermont-Ferrand

Clermont-Ferrand, France, France

RECRUITING

MeSH Terms

Conditions

Tourette Syndrome

Condition Hierarchy (Ancestors)

Basal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTic DisordersMovement DisordersHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNeurodevelopmental DisordersMental Disorders

Study Officials

  • Isabelle JALENQUES

    University Hospital, Clermont-Ferrand

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lise Laclautre

CONTACT

334.73.754.963promo_interne_drci@chu-clermontferrand.fr

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 13, 2023

First Posted

November 18, 2023

Study Start

May 6, 2024

Primary Completion

May 5, 2026

Study Completion (Estimated)

November 5, 2026

Last Updated

February 27, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)